secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2023-05-24T23:59:59+00:00
Accession:  0001213900-23-042737
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial receives Nasdaq deficiency letter for stockholders' equity shortfall
--------------------------------------------------------------------------

- On May 19, 2023, Nasdaq notified Adial that stockholders' equity of $1,439,848 as of March 31, 2023 was below the $2.5M minimum.
- Company has until July 3, 2023 to submit a compliance plan; if accepted, may receive up to 180-day extension.
- Adial remains under a separate minimum bid price deficiency with a compliance deadline of August 28, 2023.
- Management is evaluating options including a reverse stock split to regain compliance with both Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023042737/0001213900-23-042737-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390023042737/ea179159-8k_adialpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-042737

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer